2022
Mispatterning and interneuron deficit in Tourette Syndrome basal ganglia organoids
Brady M, Mariani J, Koca Y, Szekely A, King R, Bloch M, Landeros-Weisenberger A, Leckman J, Vaccarino F. Mispatterning and interneuron deficit in Tourette Syndrome basal ganglia organoids. Molecular Psychiatry 2022, 27: 5007-5019. PMID: 36447010, PMCID: PMC9949887, DOI: 10.1038/s41380-022-01880-5.Peer-Reviewed Original ResearchConceptsTourette syndromeInterneuron deficitsGABAergic interneuronsHealthy controlsNeurodevelopmental underpinningsNeuropathological deficitsBG circuitryNeuropsychiatric disordersDecreased differentiationT patientsInterneuronsAltered expressionPotential mechanismsCilia disruptionSonic hedgehogOrganoidsStem cellsTS individualsPluripotent stem cellsGli transcription factorsDeficitsOrganoid differentiationEarly stagesCholinergicPatients
2019
1.60 ANTIDEPRESSANT TREATMENT OF MDD IN PATIENTS WITH COMORBID ALCOHOL USE DISORDER: A META-ANALYSIS OF RANDOMIZED PLACEBO-CONTROLLED TRIALS WITH DISCUSSION OF PEDIATRIC IMPLICATIONS
Johnson I, Shovestul B, Niciu M, Li F, Bloch M. 1.60 ANTIDEPRESSANT TREATMENT OF MDD IN PATIENTS WITH COMORBID ALCOHOL USE DISORDER: A META-ANALYSIS OF RANDOMIZED PLACEBO-CONTROLLED TRIALS WITH DISCUSSION OF PEDIATRIC IMPLICATIONS. Journal Of The American Academy Of Child & Adolescent Psychiatry 2019, 58: s166. DOI: 10.1016/j.jaac.2019.08.082.Peer-Reviewed Original Research
2018
Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD)
Banaschewski T, Belsham B, Bloch MH, Ferrin M, Johnson M, Kustow J, Robinson S, Zuddas A. Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD). Nutrition And Health 2018, 24: 279-284. PMID: 29921155, PMCID: PMC6291899, DOI: 10.1177/0260106018772170.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderPUFA supplementationDeficit hyperactivity disorderManagement of ADHDFurther high-quality researchHyperactivity disorderPossible side effectsSmall beneficial effectRobust evidence baseChild attention-deficit hyperactivity disorderFatty acidsFrontline treatmentHigh-quality researchCurrent evidenceSide effectsPsychosocial interventionsTreatment approachesPanel consensusPatientsBeneficial effectsEvidence baseSupplementationInternational expertsDisordersAdults
2017
The efficacy of benzodiazepines as acute anxiolytics in children: A meta‐analysis
Kuang H, Johnson JA, Mulqueen JM, Bloch MH. The efficacy of benzodiazepines as acute anxiolytics in children: A meta‐analysis. Depression And Anxiety 2017, 34: 888-896. PMID: 28504861, PMCID: PMC5629100, DOI: 10.1002/da.22643.Peer-Reviewed Original ResearchConceptsEfficacy of benzodiazepinesPediatric patientsAnxiety disordersTolerability of benzodiazepinesRoom proceduresCurrent practice guidelinesStandardized mean differenceFunnel plot asymmetryOperating room proceduresProcedural settingsPediatric anxiety disordersTolerability analysisAcute managementBenzodiazepine treatmentStratified subgroupsPractice guidelinesControl groupAcute anxiolyticPublication biasAnxiolyticsBenzodiazepinesMean differencePatientsSpecific agentsAnxiety levels
2016
Commentary: Are alpha‐2 agonist really effective in children with tics with comorbid ADHD? A commentary on Whittington et al. (2016)
Bloch MH. Commentary: Are alpha‐2 agonist really effective in children with tics with comorbid ADHD? A commentary on Whittington et al. (2016). Journal Of Child Psychology And Psychiatry 2016, 57: 1005-1007. PMID: 27535650, DOI: 10.1111/jcpp.12592.Peer-Reviewed Original ResearchConceptsAlpha-2 agonistsComorbid ADHDComprehensive Behavioral InterventionAdrenergic receptor agonistAgonist medicationsAntipsychotic medicationReceptor agonistPrimary treatmentTic disordersSystematic reviewMedicationsBehavioral interventionsAgonistsEffects of ADHDEfficacyTreatmentADHDChildrenPossible explanationPatientsOCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding
Pittenger C, Adams TG, Gallezot JD, Crowley MJ, Nabulsi N, Ropchan J, Gao H, Kichuk SA, Simpson R, Billingslea E, Hannestad J, Bloch M, Mayes L, Bhagwagar Z, Carson RE. OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. Journal Of Affective Disorders 2016, 196: 87-96. PMID: 26919057, PMCID: PMC4808438, DOI: 10.1016/j.jad.2016.02.021.Peer-Reviewed Original ResearchConceptsPrepulse inhibitionObsessive-compulsive disorderReceptor availabilitySensorimotor gatingOCD patientsImpaired sensorimotor gatingOCD-like behaviorNon-depressed OCD patientsPositron emission tomographyBasal gangliaSerotonergic regulationHealthy controlsSerotonin systemPositive correlationWidespread positive correlationsDiagnostic groupsCortical regionsEmission tomographyOrbitofrontal cortexPatientsReceptor bindingOCD diagnosisSignificant correlationSignificant main effectImportant alterations
2015
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.
Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. The Journal Of Clinical Psychiatry 2015, 76: 1075-84. PMID: 26214725, PMCID: PMC4560666, DOI: 10.4088/jcp.14m09123.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialObsessive-compulsive disorderSmall open-label trialsTreatment-refractory obsessive-compulsive disorderGlutamate modulator riluzoleSignificant residual symptomsOpen-label trialSubset of patientsDSM-IV obsessive-compulsive disorderBest available treatmentsPlacebo leadRiluzole groupRefractory symptomsPartial responseSignificant morbidityResidual symptomsModerate nauseaAvailable treatmentsStandard interventionGlutamate homeostasisRiluzoleSide effectsSRI treatmentPatientsSecondary analysis
2014
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger C, Bloch MH. Pharmacological Treatment of Obsessive-Compulsive Disorder. Psychiatric Clinics Of North America 2014, 37: 375-391. PMID: 25150568, PMCID: PMC4143776, DOI: 10.1016/j.psc.2014.05.006.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPharmacological treatmentLow-dose neuroleptic medicationsSelective serotonin reuptake inhibitorsProfound clinical challengeSecond-line treatmentSerotonin reuptake inhibitorsSignificant symptomatic reliefTricyclic clomipramineAppropriate pharmacotherapyNeuroleptic medicationReuptake inhibitorsSubstantial morbiditySymptomatic reliefAvailable treatmentsClinical challengeHigh dosesOCD refractoryTreatmentDisordersMedicationsMorbidityPharmacotherapyPatientsClomipramineMeta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive–compulsive disorder
Bloch MH, Bartley CA, Zipperer L, Jakubovski E, Landeros-Weisenberger A, Pittenger C, Leckman JF. Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive–compulsive disorder. Molecular Psychiatry 2014, 19: 1025-1030. PMID: 24912494, PMCID: PMC4169729, DOI: 10.1038/mp.2014.50.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTreatment responseOCD patientsOdds ratioFurther treatment researchCase-control studyPoor treatment outcomesDifferential treatment responseSymptoms of OCDPrimary outcomeTreatment modalitiesEligible studiesTreatment outcomesPatientsElectronic searchSymptomsTotal participantsBehavioral therapyOCD treatmentDisordersSymptom dimensionsTreatment researchDSM-5Hoarding symptomsTreatment
2011
Dimensional correlates of poor insight in obsessive–compulsive disorder
Jakubovski E, Pittenger C, Torres AR, Fontenelle LF, do Rosario MC, Ferrão YA, de Mathis MA, Miguel EC, Bloch MH. Dimensional correlates of poor insight in obsessive–compulsive disorder. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2011, 35: 1677-1681. PMID: 21640153, PMCID: PMC4048951, DOI: 10.1016/j.pnpbp.2011.05.012.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPoor insightYale-Brown ObsessiveSymptom severityTreatment responseCompulsive ScaleAxis I DSMLevel of insightDetailed clinical assessmentCross-sectional studyTotal symptom severityStructured Clinical InterviewLarge clinical cohortOCD severityDimensional correlatesSocio-demographic questionnaireClinical variablesPharmacological trialsComorbid depressionBrazilian patientsClinical assessmentClinical cohortBrown AssessmentClinical InterviewPatients
2009
Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. Journal Of Affective Disorders 2009, 121: 175-179. PMID: 19577308, PMCID: PMC3974618, DOI: 10.1016/j.jad.2009.06.010.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSRI responseSymptom dimensionsOpen-label continuation phaseClinical Global Improvement ScaleGlobal Improvement ScaleCentral serotonin systemInitial positive responseYale-Brown ObsessiveContinuation phaseMinor symptomsOrdinal logistic regressionClinical trialsSerotonin systemTreatment responseSame patientImprovement ScaleSRI treatmentPatientsSignificant associationLogistic regressionCompulsive ScaleOCD patientsOCD subjectsSymptoms